Ocular Therapeutix OCUL Additional Paid-In Capital
Additional Paid-In Capital at other companies
Other financials
Where this comes from
Reported directly by Ocular Therapeutix in its filing.
Tagged under the XBRL concept us-gaap:AdditionalPaidInCapitalCommonStock.
The official record: Ocular Therapeutix’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ocular Therapeutix's additional paid-in capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ocular Therapeutix's additional paid-in capital?
- Ocular Therapeutix (OCUL) reported additional paid-in capital of $1.83B in Q1 2026.
- How has Ocular Therapeutix's additional paid-in capital changed year-over-year?
- Ocular Therapeutix's additional paid-in capital increased by 49.6% year-over-year, from $1.22B to $1.83B.
- What is the long-term trend for Ocular Therapeutix's additional paid-in capital?
- Over 5 years (2020 to 2025), Ocular Therapeutix's additional paid-in capital has grown at a 24.1% compound annual growth rate (CAGR), from $615.34M to $1.81B.
- What does additional paid-in capital mean?
- This represents the excess amount paid by investors for common shares over their par value. It is a key component of shareholders' equity that captures the capital raised through equity offerings beyond the nominal value of the stock. It reflects the historical market premium at which the company has issued its shares.